# Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors

> **NCT06088004** · PHASE1,PHASE2 · RECRUITING · sponsor: **Suzhou Abogen Biosciences Co., Ltd.** · enrollment: 218 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** ABO2011 Injection
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT06088004
- **Lead sponsor:** Suzhou Abogen Biosciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-28
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 218 (ESTIMATED)
- **Last updated:** 2025-08-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06088004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06088004, "Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06088004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*